Halozyme Therapeutics, Inc. (HALO)
68.95
+0.08
(+0.12%)
USD |
NASDAQ |
Dec 29, 16:00
68.94
0.00 (0.00%)
After-Hours: 20:00
Halozyme Therapeutics Enterprise Value: 8.917B for Dec. 29, 2025
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 527.31B |
| Merck & Co., Inc. | 287.82B |
| AIM ImmunoTech, Inc. | 0.9358M |
| Bristol Myers Squibb Co. | 144.74B |
| Protalix Biotherapeutics, Inc. | 122.76M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 175.22M |
| Revenue (Quarterly) | 354.26M |
| Total Expenses (Quarterly) | 179.04M |
| EPS Diluted (Quarterly) | 1.432 |
| Gross Profit Margin (Quarterly) | 79.39% |
| Profit Margin (Quarterly) | 49.46% |
| Earnings Yield | 6.90% |
| Operating Earnings Yield | 8.52% |
| Normalized Earnings Yield | 6.900 |